A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression

Completed · Phase 2 · Has a placebo group

Conditions studied: Bipolar Disorder

In brief

The Johns Hopkins Department of Psychiatry is conducting a research study to examine the effectiveness of riluzole in treating the depressed phase of bipolar disorder. This outpatient treatment study of medication or placebo will last 9-12 weeks. The study includes medical and psychiatric evaluations as well as time-limited medication treatment at no cost, and you will be compensated for your participation.

Key facts

Study ID

NCT00376220

Run by

Johns Hopkins University

People needed

94

Starts

2004-05-01

Expected to finish

2010-05-01

Last updated by the study team

2017-04-11

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 18-75
• Diagnosed with Bipolar I or II disorder and currently depressed
• Tried at least one antidepressant during the current episode of depression
• Currently taking either lithium, depakote, or tegretol
• Currently in outpatient treatment with a psychiatrist

You may not qualify if…

• Current psychotic symptoms
• Women who are pregnant or nursing
• Any serious, uncontrolled medical illness
• History of liver problems
• Current or past blood diseases
• Current drug or alcohol abuse
• Currently receiving Electroconvulsive Shock Therapy (ECT)
• Judged to be at serious suicidal risk

Where it is running

• Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.